PT3540062T - Permuta de cassete de região variável de imunoglobulina - Google Patents
Permuta de cassete de região variável de imunoglobulinaInfo
- Publication number
- PT3540062T PT3540062T PT191691351T PT19169135T PT3540062T PT 3540062 T PT3540062 T PT 3540062T PT 191691351 T PT191691351 T PT 191691351T PT 19169135 T PT19169135 T PT 19169135T PT 3540062 T PT3540062 T PT 3540062T
- Authority
- PT
- Portugal
- Prior art keywords
- variable region
- immunoglobulin variable
- cassette exchange
- region cassette
- exchange
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62858104P | 2004-11-16 | 2004-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3540062T true PT3540062T (pt) | 2021-07-06 |
Family
ID=36407771
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT191691351T PT3540062T (pt) | 2004-11-16 | 2005-11-16 | Permuta de cassete de região variável de imunoglobulina |
PT10014128T PT2343380T (pt) | 2004-11-16 | 2005-11-16 | Permuta de cassetes da região variável de imunoglobulina |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT10014128T PT2343380T (pt) | 2004-11-16 | 2005-11-16 | Permuta de cassetes da região variável de imunoglobulina |
Country Status (10)
Country | Link |
---|---|
US (2) | US20060134098A1 (pt) |
EP (3) | EP2343380B1 (pt) |
JP (1) | JP2008520586A (pt) |
AU (1) | AU2005306502B2 (pt) |
CA (1) | CA2587158C (pt) |
DK (2) | DK2343380T3 (pt) |
ES (3) | ES2881353T3 (pt) |
PL (2) | PL2343380T3 (pt) |
PT (2) | PT3540062T (pt) |
WO (1) | WO2006055778A2 (pt) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
DK1713503T3 (da) * | 2004-02-10 | 2013-11-04 | Univ Colorado Regents | Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde |
PL2343380T3 (pl) | 2004-11-16 | 2020-03-31 | Humanigen, Inc. | Wymiana kasety dla regionu zmiennego immunoglobuliny |
JP5707024B2 (ja) * | 2005-05-26 | 2015-04-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate | 外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤 |
EP2035448A4 (en) | 2006-06-01 | 2010-11-03 | Elan Pharm Inc | NEUROACTIVE FRAGMENTS OF APP |
WO2008063898A2 (en) * | 2006-11-08 | 2008-05-29 | Kalobios Pharmaceuticals, Inc. | Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist |
US8398972B2 (en) * | 2006-11-21 | 2013-03-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a GM-CSF antagonist |
NZ598345A (en) | 2006-11-21 | 2013-09-27 | Kalobios Pharmaceuticals Inc | Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
BRPI0807952A2 (pt) * | 2007-02-20 | 2014-06-10 | Anaptysbio Inc | Sistemas de hipermutação somática |
CN101641115B (zh) | 2007-03-08 | 2013-04-24 | 卡罗拜奥斯制药公司 | 用于实体瘤治疗的EphA3抗体 |
AU2008251943B2 (en) * | 2007-03-14 | 2013-09-05 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor B antibody |
WO2009012401A1 (en) * | 2007-07-17 | 2009-01-22 | Irm Llc | Antagonist antibodies of protease activated receptor-1 (par1) |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
EP2220117A2 (en) | 2007-11-30 | 2010-08-25 | Kalobios Pharmaceuticals, Inc. | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
WO2009114815A1 (en) | 2008-03-13 | 2009-09-17 | Dyax Corp | Libraries of genetic packages comprising novel hc cdr3 designs |
EP2281078B1 (en) | 2008-04-24 | 2014-10-22 | Dyax Corporation | Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs |
CA2722137C (en) * | 2008-04-28 | 2019-03-19 | Kalobios Pharmaceuticals, Inc. | Antibodies to granulocyte-macrophage colony-stimulating factor |
EP2393515A1 (en) | 2009-02-04 | 2011-12-14 | Kalobios Pharmaceuticals, Inc. | Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection |
US9079942B2 (en) | 2009-02-09 | 2015-07-14 | Epitomics, Inc. | CDR-anchored amplification method |
WO2010093814A1 (en) | 2009-02-11 | 2010-08-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a gm-csf antagonist |
WO2010102244A1 (en) | 2009-03-06 | 2010-09-10 | Kalobios Pharmaceuticals, Inc. | Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3 |
US8921281B2 (en) * | 2009-05-20 | 2014-12-30 | Novimmune S.A. | Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants |
EP2453906A4 (en) | 2009-07-02 | 2014-01-15 | Musc Found For Res Dev | METHOD FOR STIMULATING THE LIVER REGENERATION |
US8293483B2 (en) | 2009-09-11 | 2012-10-23 | Epitomics, Inc. | Method for identifying lineage-related antibodies |
PT2488554T (pt) | 2009-10-14 | 2019-09-13 | Humanigen Inc | Anticorpos para epha3 |
AR079336A1 (es) * | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
BR112012012873B1 (pt) * | 2009-12-22 | 2021-08-31 | F.Hoffmann-La Roche Ag | Método para fornecer uma sequência de ácido nucleico que codifica uma imunoglobulina e método para produzir uma imunoglobulina |
EP4219560A3 (en) | 2010-02-18 | 2023-08-23 | The Regents of The University of California | Integrin alpha v beta 8 neutralizing antibody |
AU2011235833A1 (en) * | 2010-04-02 | 2012-10-25 | Kalobios Pharmaceuticals, Inc. | Generation of antibodies to an epitope of interest |
BR112013020402A2 (pt) | 2011-02-11 | 2018-09-25 | Irm Llc | antagonistas pcsk9 |
US9880160B2 (en) | 2011-03-15 | 2018-01-30 | X-Body, Inc. | Antibody screening methods |
WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
WO2012170607A2 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Use of pcsk9 antagonists |
EP2764021A2 (en) * | 2011-10-05 | 2014-08-13 | Kalobios Pharmaceuticals, Inc. | Generation of antibodies to an epitope of interest that contains a phosphomimetic amino acid |
WO2013063186A2 (en) | 2011-10-26 | 2013-05-02 | Novartis Animal Health Us, Inc. | Monoclonal antibodies and methods of use |
EP2855529A4 (en) | 2012-05-24 | 2015-12-09 | Alexion Pharma Inc | HUMANIZED ANTI-FACTOR B ANTIBODIES |
WO2014084859A1 (en) | 2012-11-30 | 2014-06-05 | Novartis Ag | Molecules and methods for modulating tmem16a activities |
AR096601A1 (es) | 2013-06-21 | 2016-01-20 | Novartis Ag | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso |
EP3611191A1 (en) | 2013-12-09 | 2020-02-19 | Allakos Inc. | Anti-siglec-8 antibodies and methods of use thereof |
EP3110446B1 (en) | 2014-02-28 | 2021-12-01 | Allakos Inc. | Methods and compositions for treating siglec-8 associated diseases |
CA2943588C (en) * | 2014-06-17 | 2019-04-30 | Academia Sinica | Humanized anti-ige antibodies that crosslink cd23 on b lymphocytes but do not sensitize mast cells |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
EP3310385A4 (en) | 2015-06-17 | 2018-12-19 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
US10144768B2 (en) | 2015-12-04 | 2018-12-04 | Novartis Ag | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
WO2018053032A1 (en) | 2016-09-13 | 2018-03-22 | Humanigen, Inc. | Epha3 antibodies for the treatment of pulmonary fibrosis |
EP3532496A1 (en) | 2016-10-28 | 2019-09-04 | Banyan Biomarkers, Inc. | Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
MX2019013137A (es) | 2017-05-05 | 2020-07-14 | Allakos Inc | Metodos y composiciones para tratar enfermedades oculares alergicas. |
CN111107868A (zh) | 2017-05-24 | 2020-05-05 | 诺华股份有限公司 | 抗体细胞因子移植蛋白及使用方法 |
CA3063983A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
US10899831B2 (en) | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
US10870703B2 (en) | 2017-10-02 | 2020-12-22 | Humanigen, Inc. | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist |
US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
US10927168B2 (en) | 2017-10-02 | 2021-02-23 | Humanicen, Inc. | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
BR112021012536A2 (pt) | 2018-12-26 | 2021-09-14 | City Of Hope | Proteínas de ligação anti-ctla4 mascaradas ativáveis |
EP4301467A1 (en) | 2021-03-01 | 2024-01-10 | Xilio Development, Inc. | Combination of ctla4 and pd1/pdl1 antibodies for treating cancer |
CA3209364A1 (en) | 2021-03-01 | 2022-09-09 | Jennifer O'neil | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3742105A (en) | 1970-05-05 | 1973-06-26 | S Kuroda | Method for producing a seamless tubing |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
ES2052027T5 (es) * | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6969586B1 (en) * | 1989-05-16 | 2005-11-29 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
SK281142B6 (sk) | 1991-03-06 | 2000-12-11 | Merck Patent Gesellschaft Mit Beschr�Nkter Haftung | Humanizovaná monoklonálna protilátka, expresné vektory a farmaceutický prostriedok |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5837242A (en) * | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
CA2229043C (en) * | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
DK1034298T3 (da) * | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
WO2001094418A2 (en) | 2000-06-05 | 2001-12-13 | Corixa Corporation | Leader peptides for enhancing secretion of recombinant protein from a host cell |
AU2001268545A1 (en) | 2000-06-21 | 2002-01-08 | Alexion Pharmaceuticals, Inc. | Libraries displaying human antibody fragments with hybrid complementarity determining regions |
EP1539233B1 (en) * | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
US7371849B2 (en) | 2001-09-13 | 2008-05-13 | Institute For Antibodies Co., Ltd. | Methods of constructing camel antibody libraries |
US20030219839A1 (en) * | 2001-09-20 | 2003-11-27 | Katherine Bowdish | Anti-PDGF antibodies and methods for producing engineered antibodies |
AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
WO2003099999A2 (en) * | 2002-05-20 | 2003-12-04 | Abmaxis, Inc. | Generation and selection of protein library in silico |
US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
US20050008625A1 (en) * | 2003-02-13 | 2005-01-13 | Kalobios, Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
EP1761561B1 (en) * | 2004-01-20 | 2015-08-26 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
AU2005306997B2 (en) | 2004-10-25 | 2012-07-05 | Merck Sharp & Dohme Corp. | Anti-ADDL antibodies and uses thereof |
PL2343380T3 (pl) | 2004-11-16 | 2020-03-31 | Humanigen, Inc. | Wymiana kasety dla regionu zmiennego immunoglobuliny |
PE20090329A1 (es) * | 2007-05-30 | 2009-03-27 | Abbott Lab | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos |
-
2005
- 2005-11-16 PL PL10014128T patent/PL2343380T3/pl unknown
- 2005-11-16 EP EP10014128.2A patent/EP2343380B1/en active Active
- 2005-11-16 DK DK10014128.2T patent/DK2343380T3/da active
- 2005-11-16 ES ES19169135T patent/ES2881353T3/es active Active
- 2005-11-16 ES ES05851809T patent/ES2429541T3/es active Active
- 2005-11-16 AU AU2005306502A patent/AU2005306502B2/en not_active Ceased
- 2005-11-16 WO PCT/US2005/041825 patent/WO2006055778A2/en active Application Filing
- 2005-11-16 ES ES10014128T patent/ES2744149T3/es active Active
- 2005-11-16 US US11/282,107 patent/US20060134098A1/en not_active Abandoned
- 2005-11-16 JP JP2007541495A patent/JP2008520586A/ja active Pending
- 2005-11-16 DK DK19169135.1T patent/DK3540062T3/da active
- 2005-11-16 PT PT191691351T patent/PT3540062T/pt unknown
- 2005-11-16 PT PT10014128T patent/PT2343380T/pt unknown
- 2005-11-16 EP EP05851809.3A patent/EP1824987B1/en not_active Revoked
- 2005-11-16 PL PL19169135T patent/PL3540062T3/pl unknown
- 2005-11-16 EP EP19169135.1A patent/EP3540062B1/en active Active
- 2005-11-16 CA CA2587158A patent/CA2587158C/en active Active
-
2015
- 2015-12-14 US US14/968,709 patent/US10919983B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2006055778A3 (en) | 2006-11-23 |
PT2343380T (pt) | 2019-09-18 |
EP1824987A4 (en) | 2008-03-19 |
PL2343380T3 (pl) | 2020-03-31 |
EP1824987A2 (en) | 2007-08-29 |
JP2008520586A (ja) | 2008-06-19 |
ES2429541T3 (es) | 2013-11-15 |
CA2587158A1 (en) | 2006-05-26 |
EP2343380B1 (en) | 2019-06-12 |
US20160102152A1 (en) | 2016-04-14 |
CA2587158C (en) | 2016-01-12 |
US20060134098A1 (en) | 2006-06-22 |
AU2005306502A1 (en) | 2006-05-26 |
US10919983B2 (en) | 2021-02-16 |
EP3540062B1 (en) | 2021-05-12 |
PL3540062T3 (pl) | 2021-12-27 |
EP2343380A1 (en) | 2011-07-13 |
ES2744149T3 (es) | 2020-02-21 |
WO2006055778A2 (en) | 2006-05-26 |
EP3540062A1 (en) | 2019-09-18 |
EP1824987B1 (en) | 2013-08-21 |
DK3540062T3 (da) | 2021-06-28 |
ES2881353T3 (es) | 2021-11-29 |
DK2343380T3 (da) | 2019-09-09 |
AU2005306502B2 (en) | 2012-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2343380T (pt) | Permuta de cassetes da região variável de imunoglobulina | |
TWI307630B (en) | Immunoglobulins | |
TWI365746B (en) | Immunoglobulins | |
EP1789217A4 (en) | SANDWICH FINS | |
IL183861A0 (en) | Temperature compensanon | |
GB0423303D0 (en) | No title | |
GB0426735D0 (en) | The mobile e-commerce exchange | |
EP1718749A4 (en) | ANTI-AF-20 HUMANIZED MONOCLONAL ANTIBODY | |
ZA200504313B (en) | Cassette assembly | |
GB0417789D0 (en) | Access control | |
GB0407231D0 (en) | Variable lens | |
GB0423010D0 (en) | Cassette | |
GB0421997D0 (en) | Film | |
GB2410544B (en) | Radiator cover | |
ZA200610612B (en) | Immunoglobulins | |
GB0302699D0 (en) | Immunoglobulin | |
GB0513766D0 (en) | Immunoglobulins | |
GB0417492D0 (en) | Radiator covers | |
GB0407197D0 (en) | Immunoglobulins | |
GB0417389D0 (en) | No title | |
GB0405968D0 (en) | Neat heat | |
PL1635122T3 (pl) | Grzejnik | |
GB0423675D0 (en) | Immunoglobulins | |
GB0407193D0 (en) | Immunoglobulins | |
GB0401247D0 (en) | Router cassette |